Litfulo (ritlecitinib) — Medica

Alopecia areata

Initial criteria

Patient is age ≥ 12 years
Patient has a current episode of alopecia areata lasting for ≥ 6 months
Patient has ≥ 50% scalp hair loss
Patient has tried at least ONE of the following for alopecia areata: conventional systemic therapy (e.g., corticosteroids, methotrexate, or cyclosporine) OR a high- or super-high potency topical corticosteroid; exception to the systemic therapy trial applies if the patient has already tried Leqselvi (deuruxolitinib) or Olumiant (baricitinib)
The medication is prescribed by or in consultation with a dermatologist

Patient is age ≥ 12 years
Patient has been established on Litfulo for at least 6 months
Patient experienced a beneficial clinical response, defined as improvement from baseline in extent and density of scalp hair loss
According to the prescriber, the patient continues to require systemic therapy for alopecia areata

Initial: 6 months; Reauthorization: 1 year